Skip to content
Search

Latest Stories

UK Visa Turns Costlier For Indian, Non-EU Migrants

UK visa has turned costlier for Indian and non-EU nationals on Tuesday (8) following a decision to increase the immigration health surcharge (IHS), which is payable when the applicants request for a UK visa.

The IHS introduced in 2015 which enables the migrants to access the National Health Service (NHS) during their stay in the UK. Since the introduction of IHS, the surcharge raised more than £600 million from the migrants with UK visa valid for more than six months.


The health surcharge has been doubled on Tuesday. Accordingly, the surcharge will rise from £200 to £400 a year with the discounted rate for students and those on the Youth Mobility Scheme increasing from £150 to £300.

The migrants who apply for a UK visa on or after Tuesday should pay the new surcharges.

The latest visa surcharge hike will affect all migrants including professionals, students, as well as members of the family who move to the UK. An Indian professional with a family of four who moves to the UK to stay and work must pay £1600 a year, besides other visa costs.

The IHS hike has been opposed by the British Association of Physicians of Indian Origin, which wrote to home secretary Sajid Javid to drop it.

Immigrants who have achieved the status of permanent residents after a period of legal stay in the UK need not pay the surcharge.

The new announcement is likely to increase an estimated £220 million in extra funding for the government-run NHS. The surcharge permits any immigrant in the UK to work, study for six months or more to obtain the services of NHS akin to UK citizens.

Short-term migrants, including those on visitor visas, are generally charged for secondary care treatment by the NHS at the point of access.

More For You

Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less
Grant Thornton's Anuj Chande urges UK firms to tap booming India

Anuj Chande

Grant Thornton's Anuj Chande urges UK firms to tap booming India

INDIAN companies are well placed to support the UK’s economic growth, Eastern Eye has been told by Anuj Chande, partner and head of the South Asia Business Group at Grant Thornton.

He was speaking after the publication of Grant Thornton’s India Meets Britain Tracker 2025: The latest trends in Indian investment in the UK, which was released last week. While companies in India need little encouragement to enter the UK market, the reverse is not true.

Keep ReadingShow less